Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells

Journal of Immunology

Volumn 194, Issue 1, 2015, Pages 438-445

  Gao, Xin ^a,b   Wang, Xuefeng ^a,b   Yang, Qianting ^a,c   Zhao, Xin ^a,b   Wen, Wen ^b   Li, Gang ^a,b   Lu, Junfeng ^d   Qin, Wenxin ^e   Qi, Yuan ^a,b   Xie, Fang ^b   Jiang, Jingting ^b   Wu, Changping ^b   Zhang, Xueguang ^b   Chen, Xinchun ^c   Turnquist, Heth ^a   Zhu, Yibei ^b   Lu, Binfeng ^a,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 33; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 2; IL33 PROTEIN, MOUSE; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; IMMUNE RESPONSE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; C57BL MOUSE; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; KNOCKOUT MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOTHERAPY; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-33; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM METASTASIS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84919663306     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401344     Document Type: Article

References (42)

1. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998.
2. Finn, O. J. 2008. Cancer immunology. N. Engl. J. Med. 358: 2704-2715.
3. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
4. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce- Pages, M. Tosolini, M. Camus, A. Berger, P.Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
5. Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122-133.
6. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
7. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
8. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
9. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
10. Liew, F. Y., N. I. Pitman, and I. B. McInnes. 2010. Disease-Associated functions of IL-33: The new kid in the IL-1 family. Nat. Rev. Immunol. 10: 103-110.
11. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-Associated cytokines. Immunity 23: 479-490.
12. Chackerian, A. A., E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179: 2551-2555.
13. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS ONE 3: E3331.
14. Haraldsen, G., J. Balogh, J. Pollheimer, J. Sponheim, and A. M. Kuchler. 2009. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol. 30: 227-233.
15. Yang, Q., G. Li, Y. Zhu, L. Liu, E. Chen, H. Turnquist, X. Zhang, O. J. Finn, X. Chen, and B. Lu. 2011. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur. J. Immunol. 41: 3351-3360.
16. Smithgall, M. D., M. R. Comeau, B. R. Yoon, D. Kaufman, R. Armitage, and D. E. Smith. 2008. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20: 1019-1030.
17. Bourgeois, E., L. P. Van, M. Samson, S. Diem, A. Barra, S. Roga, J. M. Gombert, E. Schneider, M. Dy, P. Gourdy, et al. 2009. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 39: 1046-1055.
18. Bourgeois, E. A., A. Levescot, S. Diem, A. Chauvineau, H. Berges, P. Milpied, A. Lehuen, D. Damotte, J. M. Gombert, E. Schneider, et al. 2011. A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation. Eur. J. Immunol. 41: 299-305.
19. Bonilla, W. V., A. Fröhlich, K. Senn, S. Kallert, M. Fernandez, S. Johnson, M. Kreutzfeldt, A. N. Hegazy, C. Schrick, P. G. Fallon, et al. 2012. The alarmin interleukin-33 drives protective antiviral CD8? T cell responses. Science 335: 984-989.
20. Townsend, M. J., P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191: 1069-1076.
21. Lewis, J. D., M. H. Shearer, R. C. Kennedy, and R. K. Bright. 2005. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases. Cancer Res. 65: 2938-2946.
22. Lefrancais, E., and C. Cayrol. 2012. Mechanisms of IL-33 processing and secretion: Differences and similarities between IL-1 family members. Eur. Cytokine Netw. 23: 120-127.
23. Chen, L. J., X. Zheng, Y. P. Shen, Y. B. Zhu, Q. Li, J. Chen, R. Xia, S. M. Zhou, C. P. Wu, X. G. Zhang, et al. 2013. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol. Immunother. 62: 553-561.
24. Lu, B., L. Chen, L. Liu, Y. Zhu, C. Wu, J. Jiang, and X. Zhang. 2011. T-cellmediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol. Res. 50: 269-275.
25. Zhu, Y., S. Ju, E. Chen, S. Dai, C. Li, P. Morel, L. Liu, X. Zhang, and B. Lu. 2010. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J. Immunol. 185: 3174-3183.
26. Fridlender, Z. G., J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, and S. M. Albelda. 2009. Polarization of tumor-Associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16: 183-194.
27. Granot, Z., E. Henke, E. A. Comen, T. A. King, L. Norton, and R. Benezra. 2011. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20: 300-314.
28. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
29. Xu, D., W. L. Chan, B. P. Leung, Fp. Huang, R. Wheeler, D. Piedrafita, J. H. Robinson, and F. Y. Liew. 1998. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187: 787-794.
30. Tanchot, C., M. Terme, H. Pere, T. Tran, N. Benhamouda, M. Strioga, C. Banissi, L. Galluzzi, G. Kroemer, and E. Tartour. 2013. Tumor-infiltrating regulatory T cells: Phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron. 6: 147-157.
31. Gao, X., Y. Zhu, G. Li, H. Huang, G. Zhang, F. Wang, J. Sun, Q. Yang, X. Zhang, and B. Lu. 2012. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE 7: E30676.
32. Turnquist, H. R., Z. Zhao, B. R. Rosborough, Q. Liu, A. Castellaneta, K. Isse, Z. Wang, M. Lang, D. B. Stolz, X. X. Zheng, et al. 2011. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J. Immunol. 187: 4598-4610.
33. Matsushita, N., S. A. Pilon-Thomas, L. M. Martin, and A. I. Riker. 2008. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods 333: 167-179.
34. Ngoi, S. M., M. C. St Rose, A. M. Menoret, D. E. Smith, M. G. Tovey, A. J. Adler, and A. T. Vella. 2012. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc. Natl. Acad. Sci. USA 109: 10486-10491.
35. Seltmann, J., T. Werfel, and M. Wittmann. 2013. Evidence for a regulatory loop between IFN-g and IL-33 in skin inflammation. Exp. Dermatol. 22: 102-107.
36. Gao, K., X. Li, L. Zhang, L. Bai, W. Dong, K. Gao, G. Shi, X. Xia, L. Wu, and L. Zhang. 2013. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 335: 463-471.
37. Villarreal, D. O., M. C. Wise, J. N. Walters, E. L. Reuschel, M. J. Choi, N. Obeng-Adjei, J. Yan, M. P. Morrow, and D. B. Weiner. 2014. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 74: 1789-1800.
38. Chen, J., L. Duan, A. Xiong, H. Zhang, F. Zheng, Z. Tan, F. Gong, and M. Fang. 2012. Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NKT cell activation and IFN-g production in mice. J. Mol. Med. 90: 1505-1515.
39. Jovanovic, I. P., N. N. Pejnovic, G. D. Radosavljevic, J. M. Pantic, M. Z. Milovanovic, N. N. Arsenijevic, and M. L. Lukic. 2014. Interleukin-33/ ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 134: 1669-1682.
40. Volarevic, V., M. Mitrovic, M. Milovanovic, I. Zelen, I. Nikolic, S. Mitrovic, N. Pejnovic, N. Arsenijevic, and M. L. Lukic. 2012. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 56: 26-33.
41. Liu, Q., and H. R. Turnquist. 2013. Implications for Interleukin-33 in solid organ transplantation. Cytokine 62: 183-194.
42. Zhang, L., S. P. Kerkar, Z. Yu, Z. Zheng, S. Yang, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2011. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19: 751-759.